ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03724747
Recruitment Status : Not yet recruiting
First Posted : October 30, 2018
Last Update Posted : October 30, 2018
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
The study medication (BAY 2315497 Injection) is a thorium-227 labeled immuno-conjugate, specific for the prostate-specific membrane antigen (PSMA), which will be evaluated in patients with metastatic castration resistant prostate cancer. In this study, this investigational medication will be administered to patients for the first time. The primary objective of the study is to define the safety and tolerability profile and Maximal Tolerated Dose (MTD) of BAY 2315497 Injection. The secondary objectives are to determine the recommended dose for further clinical development and to investigate how the study drug is distributed and cleared from the body.

Condition or disease Intervention/treatment Phase
Metastatic Castration Resistant Prostate Cancer (mCRPC) Drug: BAY 2315497 Injection Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, First-in-human, Multi-center, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY 2315497 Injection, in Patients With Metastatic Castration Resistant Prostate Cancer
Estimated Study Start Date : October 31, 2018
Estimated Primary Completion Date : September 23, 2022
Estimated Study Completion Date : November 18, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Dose Escalation
The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
Drug: BAY 2315497 Injection
BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.

Experimental: Dose expansion:Dose regimen 1
The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY 2315497 Injection, observed in the course of the dose escalation.
Drug: BAY 2315497 Injection
BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.

Experimental: Dose expansion:Dose regimen 2
The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY 2315497 Injection, observed in the course of the dose escalation.
Drug: BAY 2315497 Injection
BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) of BAY 2315497 injection [ Time Frame: Cycle 1 (42 days) ]
    The maximum dose at which the incidence of DLTs occurring during Cycle 1 is below 30%.


Secondary Outcome Measures :
  1. Recommended dose for further clinical development of BAY 2315497 injection [ Time Frame: Up to 6 cycles (each cycle is 42 days, a maximum of 3 additional treatment cycles may be administered in case a favorable benefit risk profile is documented) ]
    The dose / regimen recommended for further clinical development will be defined after evaluation of the safety, PK and overall clinical data, collected in cycle 1 and subsequent cycles, in the dose escalation and dose expansion parts of the study.

  2. Maximum observed concentration (Cmax) of thorium [ Time Frame: Cycle 1 (From day 1 to 43) ]
  3. Area under the curve from time of dosing to 42 days after dosing [AUC(0-42)] days of thorium [ Time Frame: Cycle 1 (From day 1 to 43) ]
  4. Cmax of radium [ Time Frame: Cycle 1 (From day 1 to 43) ]
  5. AUC(0-42) days of radium [ Time Frame: Cycle 1 (From day 1 to 43) ]
  6. Cmax of total antibody [ Time Frame: Cycle 1 (From day 1 to 43) ]
  7. AUC(0-42) days of total antibody [ Time Frame: Cycle 1 (From day 1 to 43) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Ability to understand and sign an approved informed consent form.
  • Male adult patients (≥ 18 years of age).
  • ECOG PS of 0 or 1.
  • Life expectancy ≥ 6 months.
  • Histological, pathological and/or cytological confirmation of adenocarcinoma of the prostate without small cell or neuroendocrine features.
  • Previous treatment with at least one novel androgen axis drug (NAAD) (e.g. enzalutamide and/or abiraterone).
  • Patients must have prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (<50 ng/dL or <1.7 nmol/L).
  • Previous treatment with at least 1, but no more than 2 previous - taxane regimens. A taxane regimen is defined as a minimum exposure of 2 cycles of a taxane. If a patient has received only 1 taxane regimen, he is eligible, if refuses to receive a second taxane regimen, or is considered unsuitable to receive a second taxane regimen (e.g. intolerance).
  • Documented progression of mCRPC, as defined according to the Prostate Cancer Working Group 3 (PCWG3) guidelines.
  • Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements, to be conducted within 14 days before start of study drug administration:

    • Hemoglobin > 9.0 g/dL
    • Absolute neutrophil count (ANC) > 1500/mm3
    • White blood cell (WBC) count > 3000/mL
    • Platelet count > 100,000 /mm*3
    • Total bilirubin < 1,5 x upper limit of normal (ULN) (except if confirmed history of Gilbert's disease)
    • ALT and AST ≤ 2.5 x ULN
    • Serum creatinine ≤ 1.5 X ULN and glomerular filtration rate (GFR ≥ 45 mL/min/1.73 m2, according to the MDRD (Modified Diet in Renal Disease) abbreviated formula.
  • Patients with partners of childbearing potential must be willing to use highly effective methods of birth control for the time period between the first administration of BAY 2315497 Injection to at least 6 months after the last administration of the study drug.

Exclusion Criteria

  • Diffuse bone or bone-marrow involvement (i.e. "superscan").
  • Spinal cord compression or known brain metastases.
  • Known incompatibility to CT/MRI, bone scan or uncontrolled pain, which results in patient's lack of compliance with the CT/MRI and bone scan required for PCWG3 tumor assessment.
  • Clinically significant heart disease, as evidenced by myocardial infarction, arterial thrombotic events in the past 6 months, severe or unstable angina, or uncontrolled cardiovascular history.
  • Patients known to be affected by genetic defects linked to radiation Hypersensitivity.
  • Known history of myelodysplastic syndrome (MDS) / leukemia or with features suggestive of MDS/AML at any time point.
  • Concurrent or active cancer within the last 2 years with a distinct primary site or histology from the cancer being evaluated in this study, with the exception of cancer types with less than 30% likelihood of recurrence.
  • Known allergies, hypersensitivity, or intolerance to the study drug including excipients, or to contrast agents used in the diagnostic or exploratory imaging procedures required per protocol.
  • Any infection of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 Grade ≥ 2.
  • Known human immunodeficiency virus (HIV) infection.
  • Patients who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment.
  • Serious, non-healing wound, ulcer, or bone fracture.
  • Any systemic anti-neoplastic therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies], PARP inhibitors) within at least 30 days prior to day of randomization (except for Luteinizing Hormone-releasing Hormone [LHRH] or Gonadotropin-releasing Hormone [GnRH]).
  • Previous high-dose chemotherapy, needing hemopoietic stem cell rescue, is prohibited.
  • Prior major surgery (excluding prostatic biopsies) must be at least 12 weeks prior to study entry.
  • Previous treatment with therapeutic PSMA-targeted agents.
  • Previous treatment with radium-223 dichloride or other radiopharmaceuticals, including but not limited to strontium-89 or samarium-153.
  • Prior definitive radiotherapy completed less than 6 weeks before start of the study drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03724747


Contacts
Contact: Bayer Clinical Trials Contact (+)1-888-84 22937 clinical-trials-contact@bayer.com
Contact: For trial location information (Phone Menu Options '3' or '4') (+)1-888-84 22937

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Finland
HUS, Meilahden sairaala Not yet recruiting
Helsinki, Finland, 00290
Sweden
Skånes Universitetssjukhus Not yet recruiting
Lund, Sweden, 221 85
United Kingdom
Royal Marsden NHS Trust (Surrey) Not yet recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Sponsors and Collaborators
Bayer

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT03724747     History of Changes
Other Study ID Numbers: 19445
2018-001490-25 ( EudraCT Number )
First Posted: October 30, 2018    Key Record Dates
Last Update Posted: October 30, 2018
Last Verified: October 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Bayer:
Metastatic castration resistant prostate cancer, thorium-227, targeted alpha therapy,PSMA

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Antibodies
Immunoglobulins
Chelating Agents
Immunologic Factors
Physiological Effects of Drugs
Sequestering Agents
Molecular Mechanisms of Pharmacological Action